Ahmedabad-based Cadila Healthcare’s US subsidiary, Zydus Pharma USA Inc, has received approval from the United States Food and Drugs Administration (US FDA) to market a generic pain reliever Ultracet in strengths of 32.5 mg and 37.5 mg. The drug is used in the management of moderate to severe pain and widely prescribed to arthritic patients.
The company recently in the month of August received a tentative approval from the US FDA for Aripiprazole orally disintegrating tablets in the strengths of 10 mg, 15 mg, 20 mg and 30 mg. The drug is an anti-psychotic medication used in the treatment of schizophrenia.
Cadila Healthcare focuses on various areas, such as formulations (human and veterinary), new drug discovery, novel drug delivery, pharmaceutical ingredients, analytical research, phytochemistry, biotechnology, plant tissue culture, etc.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1675.20 |
| Dr. Reddys Lab | 1235.40 |
| Cipla | 1238.30 |
| Zydus Lifesciences | 942.55 |
| Lupin | 2324.25 |
| View more.. | |
MoneyWorks4Me is a SEBI-registered Investment Adviser (IA) dedicated to helping investors build long-term wealth through transparent, research-driven, conflict-free guidance. Founded in 2008, we started our journey as a Research Analyst (RA), providing deep fundamental analysis, intrinsic value insights, and long-term investing frameworks for Indian equities. In 2017, we transitioned to a full-fledged SEBI-registered Investment Adviser, strengthening our commitment to acting as a fiduciary—always putting the investor’s interest first.
To become India’s most trusted, research-powered fiduciary advisory platform—where every investor, regardless of experience, can make calm, confident, and well-reasoned investment decisions.
MoneyWorks4Me ensures this through: